Brenntag, the global heavyweight in chemical and ingredient distribution, is gearing up to spotlight a slate of new pharmaceutical innovations at CPHI India 2025, set for 25–27 November at the India Expo Centre in Greater Noida, Delhi-NCR.

 

Under the banner “Innovation That Powers Possibility,” Brenntag will roll out a portfolio of high-performance ingredients aimed at raising the bar in purity, reliability, and precision for modern drug formulations. The showcase will feature Titanium Dioxide, Citric Acids and Citrates, and Mineral Salts — staples renowned for their consistency and strict regulatory compliance.

 

A key highlight will be Brenntag’s qualified amino acids portfolio, engineered to support both upstream cell-culture production and downstream formulation. The amino acids serve multiple roles — APIs, excipients, buffers, and stabilizers — and are backed by full regulatory documentation.

 

Also on display: Brenntag’s new “Mini Tablets in Capsule” concept, a multiparticulate delivery system promising flexible dosing and better patient adherence.

 

“We define precision in everything we do — from sourcing high-purity excipients, salts, and amino acids to enabling next-generation technologies such as 3D printing,” said Romain Girard, Regional President Pharma APAC, Brenntag Specialties. 

 

“Through our Innovation and Application Centres and strong technical partnerships, we work closely with customers to turn concepts into safe, effective, and sustainable pharmaceutical solutions.”